Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Delayed Quote USD

TELA Bio, Inc. (TELA)

Compare
0.9571
-0.0429
(-4.29%)
At close: 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Antony Koblish Co-founder, President, CEO & Director 1.03M -- 1966
Mr. Roberto E. Cuca J.D. CFO & COO 674.78k -- 1968
Mr. Paul Talmo Chief Technology Officer 595.67k -- 1972
Ms. Megan Smeykal VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer -- -- 1976
Mr. D. Taylor Ocasio General Counsel & Corporate Secretary -- -- --
Ms. Jennifer Lou Armstrong Senior Vice President of Human Resources -- -- 1970
Mr. Gregory A. Firestone Chief Commercial Officer -- -- 1959
Mr. Michael Leonard Senior Vice President of Technical Operations -- -- --
Mr. Peter C. Murphy Chief Commercial Officer 542.34k -- 1973
Louisa Smith Investor Relations Contact Officer -- -- --

TELA Bio, Inc.

1 Great Valley Parkway
Suite 24
Malvern, PA 19355
United States
484 320 2930 https://www.telabio.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
209

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

TELA Bio, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 9. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC

TELA Bio, Inc. Earnings Date

Recent Events

April 7, 2025 at 12:00 AM UTC

PRE 14A: Proxy Statements

March 31, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 21, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 20, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 13, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers